Respiratory Trials·org

Pulmonary embolism · Catheter-based treatment of PE

STORM-PE randomised trial

Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism

STORM-PE trial design and results
Design Multicentre randomised controlled trial across 22 sites
Treatment Catheter-assisted vacuum thrombectomy plus anticoagulation
Control Anticoagulation alone
Population 100 patients with acute intermediate-high risk pulmonary embolism
Follow-up 48 hours for the primary endpoint
Primary endpoint Reduction in right ventricular to left ventricular ratio at 48 hours
Result Mean RV/LV ratio reduction at 48 hours was 0.52±0.37 with thrombectomy versus 0.24±0.40 with anticoagulation alone. Vital signs normalised earlier with thrombectomy, and major adverse event rates were comparable between arms.
Secondary endpoints Time to normalisation of vital signs, major adverse events, bleeding

CAVT was superior to anticoagulation alone in reducing RV/LV ratio within 48 hours in patients with intermediate-high risk PE, accompanied by earlier normalization of vital signs and major adverse event rates comparable to those for anticoagulation.

The trial authors, in the published abstract

How it has aged

A hundred patients and a surrogate endpoint: RV/LV ratio is a reasonable physiological marker but it is not survival, and this trial is far too small to speak to mortality. Read alongside PEERLESS, where the composite favouring thrombectomy was likewise driven by intermediate outcomes rather than death, and PEITHO, which showed what happens when you finally power for hard endpoints.

Publications

Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial

Lookstein RA, Konstantinides SV, Weinberg I, et al. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial. Circulation 2026 Jan 6;153(1):21-34.

  • Greater reduction in RV/LV ratio at 48 hours
  • Earlier normalisation of vital signs
  • Comparable major adverse event rates
  • Surrogate primary endpoint in only 100 patients